USA: A new study published in JAMA Oncology has revealed that glucagon-like peptide-1 receptor agonists (GLP-1RAs), widely ...

"Response’s post-GLP-1RA drug reduces weight rebound in Phase II" was originally created and published by Clinical Trials ...

The drug received accelerated approval for use in patients with metabolic dysfunction-associated steatohepatitis (MASH).

GLP-1 agonist users had a 17% lower cancer risk compared to non-users in a large retrospective study. The reductions achieved ...

As cancer progression has been linked with high glucose, adiposity, insulin resistance, and systemic inflammation, investigators studied several glucose-lowering drugs in relationship to cancer ...

New research reveals that GLP-1 receptor agonists significantly lower mortality risk in older cancer patients with type 2 ...

RDX-002, a novel iMTP inhibitor, showed promising results in a Ph2 study, reducing blood fat and weight regain after GLP-1 ...

GLP-1RAs were associated with a reduced risk for neurodegenerative and cerebrovascular diseases in type 2 diabetes and obesity.

Dietitians Australia has today launched a national call to action to the Australian Government, pleading for immediate steps ...

“GLP-1RA drugs work through a mechanism that not only controls diabetes and aids in weight loss but also has anti-inflammatory properties, which likely contributed to the reduced risk,” Nassar ...

The sample included 572 adolescents and 590 young adults eligible for GLP-1RA treatment, representing an estimated 5.8 million adolescents and 11.1 million young adults.

The GLP-1RA vs SGLT2i analysis showed no significant difference in all-cause mortality risk among patients with these cancers (HR, 1.03; 95% CI, 0.85-1.23), Dr Guo’s team reported in JAMA ...